See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot4,012▼ 0.30%WTI103.44▲ 3.99%
← NANO page
XStocksXray
Market X-Ray report · 23 October 2026

Nanobiotix S.A (NANO)

Euronext Paris · France · prices in EUR · close of 23 Oct 2026

Key indicators

Last closeEUR 25.78
52-week range13.10 – 47.66
Return, 1 month / 3 months−14.7% / −25.6%
Return, 1 year / 3 years+45.3% / +328.2%
TrendBelow its 200-day average
RSI (14)55
Volatility (1 year)74.5%
Worst drawdown (1 year)-59.2%
Average daily value traded5.12M EUR
Dividend yield–

Market X-Ray price-based

48/ 100 · High confidence · ahead of 43% of stocks on this exchange
Trend47
Momentum53
Stability (higher is calmer)19
Liquidity88
Income–

Five-year price chart navy: price · brown: 200-day average

-1.0111.4523.9236.3948.852021-112023-022024-052025-082026-10

About the company

Nanobiotix is a clinical-stage biotechnology company based in Paris, France. It develops nanoparticle-based approaches intended to improve the effectiveness of radiotherapy in cancer treatment. Its main programme uses hafnium oxide nanoparticles, given as an injectable product, to amplify the radiation dose inside tumour cells while sparing surrounding healthy tissue. The company works with hospital clinicians and research partners on studies in several tumour types, and it also pursues oncology programmes built on its nanoparticle platform.

Nanobiotix S.A trades under the code NANO on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Nanobiotix S.A (NANO) trades on the Euronext Paris in France. It last closed at EUR 25.78 on 23 October 2026.

Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 357 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 45.3% and over the last three months it fell 25.6%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Nanobiotix S.A (NANO)

The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris

Lens and metricValueScoreReading
Trend47 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-11.1%
From 52-week high-44.2%
Momentum53 · FairTypical recent returns for this exchange.
3-month return-25.6%
6-month return-10.4%
12-month return, skipping the last month70.5%
Stability (higher is calmer)19 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)74.5%
Worst drawdown, 1 year (smaller is calmer)-59.2%
Liquidity88 · StrongTrades actively.
Average daily value traded5.12M EUR
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Liquidity: Trades actively.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Stability (higher is calmer): Volatile, with deep drawdowns.

Returns

1 week+34.8%
1 month−14.7%
3 months−25.6%
6 months−10.4%
1 year+45.3%
3 years+328.2%
5 years+140.9%

Signals

50-day / 200-day average28.96 / 28.99
Golden / death cross (60 days)Death, 0 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)2.01

Technical summary

DailyBearish5 bullish · 2 neutral · 9 bearish
WeeklyBearish3 bullish · 1 neutral · 8 bearish
MonthlyBullish5 bullish · 1 neutral · 2 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 24 Oct 2026